EW Edwards Lifesciences
Structural heart franchise with TAVR moat and mitral/tricuspid runway; margins recover from charge-depressed trough.
The story
Edwards is the global leader in transcatheter aortic valve replacement (TAVR) and is building a second growth engine in mitral and tricuspid therapies (PASCAL, EVOQUE, SAPIEN M3). Its moat comes from clinical-evidence leadership, deep relationships with heart teams and regulatory barriers. Since selling Critical Care it is a pure-play structural heart franchise in late high growth. TAVR is maturing toward high-single-digit growth, while asymptomatic aortic stenosis indications and TMTT extend the reinvestment runway.
Growth of about 9% reflects TAVR at high single digits plus TMTT growing faster, below the roughly 11% 5-year CAGR as the core matures. The reported 21% margin is depressed by litigation, acquisition and separation charges, so margins recover to about 28%, below the 34% peak because of TMTT investment and pricing pressure. Incremental sales-to-capital of 1.3 replaces the trailing 0.58, which is distorted by excess cash and acquired goodwill. A 10-year horizon fits a durable but not unassailable franchise.
Value drivers
| Revenue growth (Y1) | 9.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 28.0% |
| Years to target margin | 4 |
| Sales-to-capital | 1.30 |
| Beta | 0.95 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 9.2% |
| Terminal WACC | 9.4% |
Valuation bridge
| PV of explicit FCFF | 10.16B |
| PV of terminal value | 12.96B |
| Equity value | 25.20B |
| ÷ shares → per share | $43.77 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 6.87B | 9.0% | 23.6% | 1.35B | 436.40M | 910.80M | 833.92M |
| 2 | 7.45B | 8.4% | 25.1% | 1.55B | 443.37M | 1.11B | 927.79M |
| 3 | 8.03B | 7.8% | 26.5% | 1.77B | 445.56M | 1.32B | 1.01B |
| 4 | 8.60B | 7.2% | 28.0% | 2.00B | 442.48M | 1.56B | 1.09B |
| 5 | 9.17B | 6.6% | 28.0% | 2.13B | 433.76M | 1.70B | 1.09B |
| 6 | 9.71B | 5.9% | 28.0% | 2.26B | 419.11M | 1.84B | 1.08B |
| 7 | 10.23B | 5.3% | 28.0% | 2.38B | 398.37M | 1.98B | 1.07B |
| 8 | 10.71B | 4.7% | 28.0% | 2.49B | 371.54M | 2.12B | 1.05B |
| 9 | 11.15B | 4.1% | 28.0% | 2.59B | 338.73M | 2.25B | 1.02B |
| 10 | 11.54B | 3.5% | 28.0% | 2.68B | 300.24M | 2.38B | 985.77M |
Key risks
- TAVR share loss to Medtronic, Abbott and Boston Scientific, plus hospital capacity limits on procedure growth
- TMTT adoption or reimbursement slower than expected, leaving margins diluted by R&D and commercial spend
- Clinical or safety setbacks, product liability and patent litigation, and FTC scrutiny of acquisitions such as JenaValve
Catalysts
- Label expansion and guideline updates for asymptomatic severe aortic stenosis (EARLY TAVR) driving procedure growth
- EVOQUE and SAPIEN M3 scaling with positive data and CMS coverage, lifting TMTT toward $1B+